Study for Epidemiology and Characterization of Myelodysplastic Syndromes (MDS) and Juvenile Myelomonocytic Leucemia (JMML) in Childhood

Launched by UNIVERSITY HOSPITAL FREIBURG · Apr 18, 2008

Keywords

ClinConnect Summary

This clinical trial is focused on understanding two serious blood conditions in children and teenagers: Myelodysplastic Syndromes (MDS) and Juvenile Myelomonocytic Leukemia (JMML). The main goal of the study is to improve how doctors diagnose these conditions by using standardized methods to examine blood samples. Researchers will look at how often different types of MDS occur in young patients and analyze specific genetic changes that may be present. This could help identify new treatment options and understand the conditions better.

To participate in the trial, children and adolescents must be under 18 years old and have a confirmed diagnosis of MDS or JMML. Caregivers must provide their consent, and whenever possible, the children’s agreement as well. Participants can expect to undergo various tests that will help researchers gather important information about their condition and overall survival. It’s important to note that this trial is currently active but not recruiting new participants.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Written informed consent by the caretakers and whenever possible the patient's assent.
• • Confirmed diagnosis of MDS or JMML (morphology, cytogenetics)
• • Myeloid leukemia of Down syndrome (patients aged \> 6 years).
• • Age less than 18 years
• Exclusion Criteria:
• • Denied informed consent and/or assent by caretakers/patient.
• • Myeloid leukemia of Down syndrome (patients \< 6 years).
• • Participation in another study within the last 4 weeks (except for therapy optimizing studies in cancer or bone marrow failure disorders and studies in diagnostics).